Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01967485 · ClinicalTrials.gov registry record · NA

Text Messaging Adherence to Stimulant Medication

A NA study of Attention Deficit Hyperactivity Disorder, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
35
Enrollment target
1
Study location

NCT01967485: Completed NA study of Attention Deficit Hyperactivity Disorder, sponsored by Massachusetts General Hospital.

NCT01967485 is a NA study of Attention Deficit Hyperactivity Disorder that has completed, run by Massachusetts General Hospital. The registered enrollment target is 35 participants, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01967485, a NA study of Attention Deficit Hyperactivity Disorder, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
35 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if an individualized text messaging intervention for the parents of children with Attention Deficit/Hyperactivity Disorder is effective in improving medication adherence and disease management.

Interventions

  • OTHER Treatment as usual
  • OTHER Text- Messaging

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2014-01
Est. Completion 2016-09
Phase NA

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT01967485

The ClinicalTrials.gov registry entry for NCT01967485 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 206-participant average among 88 other Attention Deficit Hyperactivity Disorder trials with a reported enrollment target (83% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Attention Deficit Hyperactivity Disorder appearing as the primary indexed condition, and to 2 interventions - of which Treatment as usual is the first listed.

NCT01967485 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT01967485 about?

NCT01967485 is a clinical study titled "Text Messaging Adherence to Stimulant Medication". The purpose of this study is to determine if an individualized text messaging intervention for the parents of children with Attention Deficit/Hyperactivity Disorder is effective in improving medication adherence and disease management.

What is the current status of trial NCT01967485?

This trial is currently completed. It is a NA study. The enrollment target is 35 participants. The study started on 2014-01. Estimated completion is 2016-09.

What conditions does trial NCT01967485 study?

This clinical trial studies the following conditions: Attention Deficit Hyperactivity Disorder.

What interventions are being tested in trial NCT01967485?

The interventions under investigation include: Treatment as usual (OTHER), Text- Messaging (OTHER).

Who is sponsoring clinical trial NCT01967485?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01967485 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Attention Deficit Hyperactivity Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.